Michael Miller, MD, FACC, FAHA, FNLA
Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Ac...
Eliot Brinton, MD, FAHA, FNLA
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Prevention of ASCVD in Women Through Lipid Management in the New Era
Michel Farnier, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl ...
